ViiV Healthcare - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 39

ViiV Healthcare – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “ViiV Healthcare - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- ViiV Healthcare - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ViiV Healthcare human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ViiV Healthcare with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ViiV Healthcare’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate ViiV Healthcare’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ViiV Healthcare in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ViiV Healthcare’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ViiV Healthcare.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ViiV Healthcare and identify potential opportunities in those areas.

List of Tables
List of Figures
ViiV Healthcare Snapshot
ViiV Healthcare Overview
Key Information
Key Facts
ViiV Healthcare – Research and Development Overview
Key Therapeutic Areas
ViiV Healthcare – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
ViiV Healthcare – Pipeline Products Glance
ViiV Healthcare – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
ViiV Healthcare Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ViiV Healthcare – Drug Profiles
1349572
Product Description
Mechanism of Action
R&D Progress
2248761
Product Description
Mechanism of Action
R&D Progress
GSK706769
Product Description
Mechanism of Action
R&D Progress
PF-232798
Product Description
Mechanism of Action
R&D Progress
S/GSK1265744
Product Description
Mechanism of Action
R&D Progress
UK-453061
Product Description
Mechanism of Action
R&D Progress
GSK706769
Product Description
Mechanism of Action
R&D Progress
PF-3716539
Product Description
Mechanism of Action
R&D Progress
ViiV Healthcare – Pipeline Analysis
ViiV Healthcare – Pipeline Products by Therapeutic Class
ViiV Healthcare Pipeline Products By Target
ViiV Healthcare – Pipeline Products by Route of Administration
ViiV Healthcare – Pipeline Products by Molecule Type
ViiV Healthcare – Recent Pipeline Updates
ViiV Healthcare – Locations And Subsidiaries
Head Office
Recent Developments
Nov 23, 2010: Idenix Receives $20 Million Milestone Payment From ViiV Healthcare For Initiation Of Phase IIb Trial Of '761
Oct 21, 2010: Shionogi-ViiV Initiates Phase III Clinical Program For Investigational Once-Daily HIV Integrase Inhibitor
Jul 22, 2010: Shionogi-ViiV Presents Positive Data From Two Phase IIb Studies Of S/GSK1349572 At International AIDS Conference
Jul 21, 2010: Shionogi-ViiV Healthcare Initiates Phase III Development Program For S/GSK1349572 In Treatment Of HIV
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Dec 22, 2009: GSK warned that Lexiva may be associated with cardiac problems
Nov 20, 2009: FDA Approves Expanded Use of Selzentry for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time
Oct 08, 2009: FDA Advisory Committee Recommends Approval of Pfizer’s Selzentry for Use in Patients Starting HIV Therapy for the First Time
Jul 21, 2009: 96-Week MERIT ES Analysis Shows Efficacy Of Pfizer’s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Charter Schools - Global Outlook
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Distance Learning - Global Outlook
• Global Education Industry Forecast to 2016 - Focus on Emerging Markets
• Defense Robotics - Global Strategic Business Report